Our Purpose
We are at the forefront of minimally invasive therapies for peripheral artery disease, venous disease, vessel trauma, and cancer.
Driving Meaningful Innovation
Transforming Arterial Disease Treatment
An estimated 200 million individuals worldwide are affected by Peripheral Arterial Disease (PAD). Boston Scientific has developed a robust range of products to address this market, positioning uniquely to provide physicians and healthcare systems with a comprehensive set of solutions for patient care.
Comprehensive Solutions for Venous Disorders
Boston Scientific’s extensive venous product portfolio includes a leading array of technologies, such as venous stents, endovenous chemical ablation, ultrasound-assisted clot dissolution devices, mechanical thrombectomy, and advanced imaging catheters.
Conditions Treated with Our Devices:
Impact Metrics
200 million
Over 200 million people suffer from PAD worldwide.²
765,000
More than 765,000 cases of DVT occur annually in the U.S. and Europe.³
800,000
Approximately 800,000 new liver cancer diagnoses are made each year globally.⁴
22 million
More than 22 million patients are affected by Critical Limb Ischemia Worldwide.⁵
Our Product Offerings
- Peripheral Balloons and Stents
- Crossing Technology
- Solutions for Venous Obstruction
- Imaging Solutions
- Embolization Technologies
- Access and Delivery Systems
- Drug-Eluting Technologies
- Guidewires & Accessories
- Clot Management Tools
- Treatments for Venous Insufficiency
- Tumor Ablation and Treatment Options
Product Spotlights
Eluvia™ Drug-Eluting Vascular Stent System
The Eluvia™ Drug-Eluting Vascular Stent System is specifically developed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The Eluvia stent utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel for a one-year timeframe, designed to prevent tissue regrowth that might otherwise block the stented artery. The Eluvia stent was approved by the FDA based on findings from the IMPERIAL trial, in which the Eluvia stent demonstrated superior results in the first superficial femoral artery head-to-head drug-eluting stent trial.
Ranger™ Drug-Coated Balloon
The Ranger™ Drug-Coated Balloon was developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). It was designed with a low therapeutic drug dose and proprietary coating which efficiently transfers the drug into the diseased tissue, resulting in high primary patency rates and low systemic drug exposure for patients. The low-profile platform of the balloon also assists clinicians in performing streamlined procedures and navigating through challenging anatomy in order to deliver consistent therapy.
Interlock and IDC Detachable Embolization Coils
Interlock and IDC (Interlocking Detachable Coils) Embolization Coils are advanced medical devices used primarily in interventional radiology for the treatment of vascular malformations, aneurysms, and other conditions requiring targeted vascular occlusion.
Jetstream™ Atherectomy System
The Jetstream™ Atherectomy System is a medical device used primarily in the treatment of peripheral artery disease (PAD) and coronary artery disease (CAD). This system utilizes a unique combination of mechanical ablation and aspiration to remove atherosclerotic plaque from the arterial walls, thereby restoring blood flow.
EKOS™ Endovascular System
The EKOS™ Endovascular System is the first endovascular device approved by the FDA for treating pulmonary embolism (PE). It utilizes targeted ultrasound energy along with clot-dissolving medications to effectively restore blood flow in patients suffering from PE.
ANGIOJET™ Peripheral Thrombectomy System
The ANGIOJET™ Peripheral Thrombectomy System is a medical device designed to remove thrombus (blood clots) from peripheral blood vessels. This system utilizes a technique called “hydrolytic thrombectomy,” which employs a combination of high-velocity saline jets to fragment and aspirate clots from the affected area, improving blood flow and restoring vessel patency.
